# Cetuximab

## Erbitux inj 100mg/20mL \(sample\)

| 藥物代碼 | IERB0 |
| :--- | :--- |
| 適應症 | Colorectal cancer, metastatic: Treatment of KRAS wild-type \(without mutation\), epidermal growth factor receptor \(EGFR\)-expressing metastatic colorectal cancer as determined by approved tests \(in combination with FOLFIRI \[irinotecan, fluorouracil, and leucovorin\] as first-line treatment, in combination with irinotecan \[in patients refractory to irinotecan-based chemotherapy\], or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan\).Limitation of use: Cetuximab is not indicated for the treatment of RAS-mutant colorectal cancer or when results of the RAS mutation tests are unknown. Head and neck cancer, squamous cell: Treatment of squamous cell cancer of the head and neck \(as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease\). |
| 副作用 | Mild or moderate infusion-related reactions eg fever, chills, dizziness or dyspnea; mild to moderate mucositis, increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea, nausea, vomiting; dehydration, hypocalcemia, anorexia; fatigue. |
| 禁忌 | Known severe hypersensitivity reactions to cetuximab. |
| 藥物保存方式 | 2-8°C |
| 用法用量 | Initial dose: 400 mg/m2 once weekly with infusion period of 120 mins. Subsequent doses: 250 mg/m2 once weekly with infusion period of 60 mins. Max infusion rate must not exceed 10 mg/min. Chemotherapy must not be administered earlier than 1 hr after the end of the Erbitux infusion. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 輸注本藥品一定要單獨使用一條管線，輸注結束時一定要用無菌的生理食鹽水沖洗管線。 |

## Erbitux inj 100mg/20mL

| 藥物代碼 | IERB2 |
| :--- | :--- |
| 適應症 | Colorectal cancer, metastatic: Treatment of KRAS wild-type \(without mutation\), epidermal growth factor receptor \(EGFR\)-expressing metastatic colorectal cancer as determined by approved tests \(in combination with FOLFIRI \[irinotecan, fluorouracil, and leucovorin\] as first-line treatment, in combination with irinotecan \[in patients refractory to irinotecan-based chemotherapy\], or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan\).Limitation of use: Cetuximab is not indicated for the treatment of RAS-mutant colorectal cancer or when results of the RAS mutation tests are unknown. Head and neck cancer, squamous cell: Treatment of squamous cell cancer of the head and neck \(as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease\). |
| 副作用 | Mild or moderate infusion-related reactions eg fever, chills, dizziness or dyspnea; mild to moderate mucositis, increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea, nausea, vomiting; dehydration, hypocalcemia, anorexia; fatigue. |
| 禁忌 | Known severe hypersensitivity reactions to cetuximab. |
| 藥物保存方式 | 2-8°C |
| 用法用量 | Initial dose: 400 mg/m2 once weekly with infusion period of 120 mins. Subsequent doses: 250 mg/m2 once weekly with infusion period of 60 mins. Max infusion rate must not exceed 10 mg/min. Chemotherapy must not be administered earlier than 1 hr after the end of the Erbitux infusion. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | Administer through a low protein-binding 0.22 micrometer in-line filter. Administer via infusion pump or syringe pump at a rate not to exceed 10 mg/minute. Do not administer as IV push or bolus. Do not shake or dilute. |
| 注意事項 | 1. 輸注本藥品一定要單獨使用一條管線，輸注結束時一定要用無菌的生理食鹽水沖洗管線。 |

